Pituitary adenylate cyclase-activating polypeptide deficient mice show length abnormalities of the axon initial segment.

Atomoxetine (ATX) Attention-deficit/hyperactivity disorder (ADHD) Axon initial segment (AIS) Neurodevelopmental disorder (NDD) Pituitary adenylate cyclase-activating polypeptide (PACAP)

Journal

Journal of pharmacological sciences
ISSN: 1347-8648
Titre abrégé: J Pharmacol Sci
Pays: Japan
ID NLM: 101167001

Informations de publication

Date de publication:
Nov 2023
Historique:
received: 30 06 2023
revised: 08 08 2023
accepted: 25 08 2023
medline: 29 9 2023
pubmed: 29 9 2023
entrez: 28 9 2023
Statut: ppublish

Résumé

We previously found that pituitary adenylate cyclase-activating polypeptide (PACAP)-deficient (PACAP

Identifiants

DOI: 10.1016/j.jphs.2023.08.006 PMID: 37770159
pubmed: 37770159
pii: S1347-8613(23)00050-6
doi: 10.1016/j.jphs.2023.08.006
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

175-182

Informations de copyright

Copyright © 2023 The Authors. Production and hosting by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have influenced the work reported in this study.

Auteurs

Misaki Iwahashi (M)

Department of Child Development and Molecular Brain Science, United Graduate School of Child Development, Osaka University, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan.

Takeshi Yoshimura (T)

Department of Child Development and Molecular Brain Science, United Graduate School of Child Development, Osaka University, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan. Electronic address: tyoshimu@ugscd.osaka-u.ac.jp.

Wakana Harigai (W)

Department of Child Development and Molecular Brain Science, United Graduate School of Child Development, Osaka University, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan.

Kazuhiro Takuma (K)

Department of Pharmacology, Graduate School of Dentistry, Osaka University, 1-8 Yamadaoka, Suita, Osaka 565-0871, Japan; Molecular Research Center for Children's Mental Development, United Graduate School of Child Development, Osaka University, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan.

Hitoshi Hashimoto (H)

Molecular Research Center for Children's Mental Development, United Graduate School of Child Development, Osaka University, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan; Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan; Transdimensional Life Imaging Division, Institute for Open and Transdisciplinary Research Initiatives, Osaka University, 2-1 Yamadaoka, Suita, Osaka, 565-0871, Japan; Division of Bioscience, Institute for Datability Science, Osaka University, 2-8 Yamadaoka, Suita, Osaka, 565-0871, Japan; Department of Molecular Pharmaceutical Science, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.

Taiichi Katayama (T)

Department of Child Development and Molecular Brain Science, United Graduate School of Child Development, Osaka University, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan.

Atsuko Hayata-Takano (A)

Department of Pharmacology, Graduate School of Dentistry, Osaka University, 1-8 Yamadaoka, Suita, Osaka 565-0871, Japan; Molecular Research Center for Children's Mental Development, United Graduate School of Child Development, Osaka University, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan; Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan. Electronic address: hayata.atsuko.dent@osaka-u.ac.jp.

Classifications MeSH